Recruiting
Phase 1
Phase 2

Propranolol

Sponsor:

June Wu

Code:

NCT06833320

Conditions

Postoperative Chylothorax

Congenital Heart Disease

Open Heart Surgery

Chylothorax

Eligibility Criteria

Sex: All

Age: 0 - 18

Healthy Volunteers: Not accepted

Interventions

Propranolol Hydrochloride

Placebo

Study Details

Brief summary:

Postoperative chylothorax is a serious complication after open heart surgery for pediatric patients with congenital heart disease (CHD). While it was thought to be mechanical injury to the thoracic duct, recent research demonstrated that there are intrinsically abnormal lung lymphatics in CHD patients, and after open heart surgery, the fluid shifts that occur overwhelms these abnormal lung lymphatics. As a result, postoperative chylothorax occurs. Propranolol has been found to be helpful in resolving postoperative chylothorax very quickly (9 days) in a subset of postoperative chylothorax patients (60%). However, it is not known why some patients respond and some do not. The investigators hypothesize that propranolol is safe to use in this patient population, and that certain clinical factors will predict propranolol response, but more importantly, some clinical factors can be optimize to allow more patients with postoperative chylothorax to respond to and benefit from propranolol. In order to improve the understanding of how propranolol works and to maximize benefit to patients, the investigators propose to perform a prospective, randomized, double-blind clinical trial to learn how to best use propranolol in patients with postoperative chylothorax.

Conditions

Postoperative Chylothorax

Congenital Heart Disease

Open Heart Surgery

Chylothorax

Study ID

NCT06833320

Start date

Sep 9, 2025

Status verified date

Nov, 2026

Completion date

Jan 1, 2031

Anticipated

Primary completion date

Sep 30, 2028

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 0 - 18

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • ≥7 days and ≤18 years old at time of original cardiac surgery
  • Congenital structural cardiac anomaly necessitating surgical correction. Examples include but are not limited to: ASD, VSD, single ventricles, HLHS, Tetralogy of Fallot, transposition of great vessels, AV canal, heart transplant
  • developed high output postoperative chylothorax (≥10mL/kg/day), or
  • persistent chylous drainage at any volume for ≥7 days after open heart surgery for a congenital cardiac defect
  • ≥70% lymphocytes, or
  • pleural triglyeride (TG) ≥ half of serum TG, or chylomicron positive

  • for patients with lower than normal serum lymphocyte count (agedependent), ≥60% lymphocytes in pleural fluids
  • Must have measurable output (chylothorax output in mL)
  • Any level of respiratory support (room air, supplemental oxygen, CPAP/BIPAP, ventilatory support)
  • Any level of inpatient support (ICUs, step-down units, floor)
  • Study participants can be on concomitant treatment for postoperative chylothorax started prior to study initiation
  • Study participants can continue on on-going treatment for their primary cardiac other medical conditions
  • Study participants can initiate new treatments for their primary cardiac or other medical conditions during trial period
  • Adequate renal function
  • Not on dialysis
  • No hemodynamically unstable bradycardia
  • No systolic hypotension not corrected by pressor support
  • Not in 2nd or 3rd degree heart block
  • No history of asthma
  • A parent or a legal guardian must sign a written informed consent and HIPAA Form
  • Patients will be required to also be enrolled in a related study (AAAQ6902) which collects chylothorax fluid for cell isolation and genetic analysis

Exclusion Criteria:

  • Pregnancy
  • Renal failure at time of enrollment
  • Hypotension despite pressor support
  • Unstable bradycardia without capacity for pacing
  • History of asthma or chronic bronchodilator therapy
  • Uncontrolled hypoglycemia or hyperglycemia as per investigators' judgment
  • Study participant will be removed from study if they failed 2 consecutive attempts to initiate propranolol (>10% drop in BP/HR from age-adjusted normative range)
  • Study participant experiences ≥ Grade 3 AE (SAE)

Study Design

Enrollment

50 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

placebo comparator: Placebo

Placebo suspension will only have Ora-Blend

active comparator: Propranolol hydrochloride

Subjects will be randomized to receive 2mg/kg/day. Propranolol will be administered orally, either as a tablet or as a solution, in equal divided doses three times a day.

Interventions

Propranolol Hydrochloride

Propranolol will be administered as tablets. Participants who are too young to swallow pills will be given propranolol solution.

Placebo

Placebo suspension will only have Ora-Blend Medication Flavoring and Suspension Vehicle

Primary outcome measure

  • Daily heart rates recorded in flow chart and 1 hour after each dose [ Time Frame: 24 days ]
  • Daily blood pressures recorded in flow chart and 1 hour after each dose [ Time Frame: 24 days ]
  • Daily glucose levels [ Time Frame: 24 days ]
  • Expected and unexpected AEs, per patient [ Time Frame: 24 days ]
  • Days with documented chest tube (# days), CXR [ Time Frame: 24 days ]
  • Initial volume of fluid drained (mL, mL/kg/day) [ Time Frame: Day 0 ]
  • Days hospitalized [ Time Frame: 6 months ]

Central Contacts and Locations

Central contacts

Locations

Columbia University Irving Medical Center/NewYork-Presbyterian

Recruiting

New York, New York, United States, 10032

More Information

Sponsor

June Wu

Last update posted

Nov 18, 2026

Last verified

Nov, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-11-19. This information was provided to ClinicalTrials.gov by June Wu on 2026-11-18. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.